
    
      The present randomized, controlled, parallel-grouped trial included 48 patients (aged 18 to
      75 years) suffering from oral potentially premalignant lesions. Patients were randomly
      assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B:
      Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)
    
  